Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells

Matthew F. Kalady, Mark W. Onaitis, Sirisha Emani, Zeinab Abdul-Wahab, Scott K. Pruitt, Douglas Tyler

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

RNA-based dendritic cell immunotherapy with the use of total tumor RNA provides the potential to generate a polyclonal immune response to multiple known and unknown tumor antigens without HLA restriction. Our study evaluated this approach as potential immunotherapy for patients with pancreatic cancer. Dendritic cells were generated using adherent monocytes isolated from peripheral blood of patients with pancreatic cancer and evaluated phenotypically by flow cytometry to determine whether dendritic cells could be generated from the blood of patients with pancreatic cancer. Immature dendritic cells were transfected with mRNA encoding full-length carcinoembryonic antigen (CEA) or pancreatic cancer total tumor messenger RNA, and then matured. Matured dendritic cell phenotypes were also analyzed by flow cytometry. Transfected, matured dendritic cells were used to stimulate autologous T cells, and the resultant antigen-specific effector T cells were analyzed by interferon-γ Elispot assay. Immature dendritic cells with characteristic phenotypic markers CD40, CD80, and CD86 were successfully isolated from the blood of patients with pancreatic cancer. Incubation with maturation agents increased expression of CD80 and CD83, demonstrating the induction of a mature antigen-presenting phenotype. Dendritic cells transfected with a pancreatic cancer-associated antigen (CEA) generated antigen-specific T cells (P<0.05). Dendritic cells transfected with autologous total tumor pancreatic cancer RNA generated T cells that specifically recognized HLA-matched pancreatic cancer cell lines (P<0. 05 compared to control cell lines). Dendritic cells from patients with pancreatic cancer maintain the ability to translate and process transfected RNA and serve as mature antigen-presenting cells. These RNA-transfected dendritic cells from pancreatic cancer patients successfully generate specific T cells against the pancreatic cancer-associated antigen CEA as well as T cells that specifically recognize pancreatic cancer cells. These data suggest that total tumor RNA-pulsed dendritic cells may have potential as an adjuvant immunotherapy for patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)175-182
Number of pages8
JournalJournal of Gastrointestinal Surgery
Volume8
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Dendritic Cells
RNA
T-Lymphocytes
Neoplasms
Antigens
Immunotherapy
Carcinoembryonic Antigen
Flow Cytometry
Phenotype
Cell Line
Messenger RNA
Neoplasm Antigens
Antigen-Presenting Cells
Interferons
Monocytes

Keywords

  • Carcinoembryonic antigen
  • Dendritic cells
  • Immunotherapy
  • Pancreatic cancer
  • Total tumor RNA

ASJC Scopus subject areas

  • Surgery

Cite this

Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. / Kalady, Matthew F.; Onaitis, Mark W.; Emani, Sirisha; Abdul-Wahab, Zeinab; Pruitt, Scott K.; Tyler, Douglas.

In: Journal of Gastrointestinal Surgery, Vol. 8, No. 2, 02.2004, p. 175-182.

Research output: Contribution to journalArticle

Kalady, Matthew F. ; Onaitis, Mark W. ; Emani, Sirisha ; Abdul-Wahab, Zeinab ; Pruitt, Scott K. ; Tyler, Douglas. / Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. In: Journal of Gastrointestinal Surgery. 2004 ; Vol. 8, No. 2. pp. 175-182.
@article{c0abeb752d694d92af20b722580fb388,
title = "Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells",
abstract = "RNA-based dendritic cell immunotherapy with the use of total tumor RNA provides the potential to generate a polyclonal immune response to multiple known and unknown tumor antigens without HLA restriction. Our study evaluated this approach as potential immunotherapy for patients with pancreatic cancer. Dendritic cells were generated using adherent monocytes isolated from peripheral blood of patients with pancreatic cancer and evaluated phenotypically by flow cytometry to determine whether dendritic cells could be generated from the blood of patients with pancreatic cancer. Immature dendritic cells were transfected with mRNA encoding full-length carcinoembryonic antigen (CEA) or pancreatic cancer total tumor messenger RNA, and then matured. Matured dendritic cell phenotypes were also analyzed by flow cytometry. Transfected, matured dendritic cells were used to stimulate autologous T cells, and the resultant antigen-specific effector T cells were analyzed by interferon-γ Elispot assay. Immature dendritic cells with characteristic phenotypic markers CD40, CD80, and CD86 were successfully isolated from the blood of patients with pancreatic cancer. Incubation with maturation agents increased expression of CD80 and CD83, demonstrating the induction of a mature antigen-presenting phenotype. Dendritic cells transfected with a pancreatic cancer-associated antigen (CEA) generated antigen-specific T cells (P<0.05). Dendritic cells transfected with autologous total tumor pancreatic cancer RNA generated T cells that specifically recognized HLA-matched pancreatic cancer cell lines (P<0. 05 compared to control cell lines). Dendritic cells from patients with pancreatic cancer maintain the ability to translate and process transfected RNA and serve as mature antigen-presenting cells. These RNA-transfected dendritic cells from pancreatic cancer patients successfully generate specific T cells against the pancreatic cancer-associated antigen CEA as well as T cells that specifically recognize pancreatic cancer cells. These data suggest that total tumor RNA-pulsed dendritic cells may have potential as an adjuvant immunotherapy for patients with pancreatic cancer.",
keywords = "Carcinoembryonic antigen, Dendritic cells, Immunotherapy, Pancreatic cancer, Total tumor RNA",
author = "Kalady, {Matthew F.} and Onaitis, {Mark W.} and Sirisha Emani and Zeinab Abdul-Wahab and Pruitt, {Scott K.} and Douglas Tyler",
year = "2004",
month = "2",
doi = "10.1016/j.gassur.2003.11.003",
language = "English (US)",
volume = "8",
pages = "175--182",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells

AU - Kalady, Matthew F.

AU - Onaitis, Mark W.

AU - Emani, Sirisha

AU - Abdul-Wahab, Zeinab

AU - Pruitt, Scott K.

AU - Tyler, Douglas

PY - 2004/2

Y1 - 2004/2

N2 - RNA-based dendritic cell immunotherapy with the use of total tumor RNA provides the potential to generate a polyclonal immune response to multiple known and unknown tumor antigens without HLA restriction. Our study evaluated this approach as potential immunotherapy for patients with pancreatic cancer. Dendritic cells were generated using adherent monocytes isolated from peripheral blood of patients with pancreatic cancer and evaluated phenotypically by flow cytometry to determine whether dendritic cells could be generated from the blood of patients with pancreatic cancer. Immature dendritic cells were transfected with mRNA encoding full-length carcinoembryonic antigen (CEA) or pancreatic cancer total tumor messenger RNA, and then matured. Matured dendritic cell phenotypes were also analyzed by flow cytometry. Transfected, matured dendritic cells were used to stimulate autologous T cells, and the resultant antigen-specific effector T cells were analyzed by interferon-γ Elispot assay. Immature dendritic cells with characteristic phenotypic markers CD40, CD80, and CD86 were successfully isolated from the blood of patients with pancreatic cancer. Incubation with maturation agents increased expression of CD80 and CD83, demonstrating the induction of a mature antigen-presenting phenotype. Dendritic cells transfected with a pancreatic cancer-associated antigen (CEA) generated antigen-specific T cells (P<0.05). Dendritic cells transfected with autologous total tumor pancreatic cancer RNA generated T cells that specifically recognized HLA-matched pancreatic cancer cell lines (P<0. 05 compared to control cell lines). Dendritic cells from patients with pancreatic cancer maintain the ability to translate and process transfected RNA and serve as mature antigen-presenting cells. These RNA-transfected dendritic cells from pancreatic cancer patients successfully generate specific T cells against the pancreatic cancer-associated antigen CEA as well as T cells that specifically recognize pancreatic cancer cells. These data suggest that total tumor RNA-pulsed dendritic cells may have potential as an adjuvant immunotherapy for patients with pancreatic cancer.

AB - RNA-based dendritic cell immunotherapy with the use of total tumor RNA provides the potential to generate a polyclonal immune response to multiple known and unknown tumor antigens without HLA restriction. Our study evaluated this approach as potential immunotherapy for patients with pancreatic cancer. Dendritic cells were generated using adherent monocytes isolated from peripheral blood of patients with pancreatic cancer and evaluated phenotypically by flow cytometry to determine whether dendritic cells could be generated from the blood of patients with pancreatic cancer. Immature dendritic cells were transfected with mRNA encoding full-length carcinoembryonic antigen (CEA) or pancreatic cancer total tumor messenger RNA, and then matured. Matured dendritic cell phenotypes were also analyzed by flow cytometry. Transfected, matured dendritic cells were used to stimulate autologous T cells, and the resultant antigen-specific effector T cells were analyzed by interferon-γ Elispot assay. Immature dendritic cells with characteristic phenotypic markers CD40, CD80, and CD86 were successfully isolated from the blood of patients with pancreatic cancer. Incubation with maturation agents increased expression of CD80 and CD83, demonstrating the induction of a mature antigen-presenting phenotype. Dendritic cells transfected with a pancreatic cancer-associated antigen (CEA) generated antigen-specific T cells (P<0.05). Dendritic cells transfected with autologous total tumor pancreatic cancer RNA generated T cells that specifically recognized HLA-matched pancreatic cancer cell lines (P<0. 05 compared to control cell lines). Dendritic cells from patients with pancreatic cancer maintain the ability to translate and process transfected RNA and serve as mature antigen-presenting cells. These RNA-transfected dendritic cells from pancreatic cancer patients successfully generate specific T cells against the pancreatic cancer-associated antigen CEA as well as T cells that specifically recognize pancreatic cancer cells. These data suggest that total tumor RNA-pulsed dendritic cells may have potential as an adjuvant immunotherapy for patients with pancreatic cancer.

KW - Carcinoembryonic antigen

KW - Dendritic cells

KW - Immunotherapy

KW - Pancreatic cancer

KW - Total tumor RNA

UR - http://www.scopus.com/inward/record.url?scp=1242306254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242306254&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2003.11.003

DO - 10.1016/j.gassur.2003.11.003

M3 - Article

VL - 8

SP - 175

EP - 182

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 2

ER -